Tag: KDC-MN-250

  • Gepirone

    5-HT1A partial agonist

    An azapirone 5-HT1A partial agonist developed for major depressive disorder; FDA-approved in 2023 after a 30-year development cycle.

    Abstract

    Gepirone (4,4-dimethyl-1-{4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl}-2,6-piperidinedione; CAS 83928-76-1; molecular formula C19H29N5O2; molecular weight 359.47) is an azapirone 5-HT1A partial agonist developed by Bristol-Myers Squibb and Fabre-Kramer over a 30-plus-year development cycle, ultimately approved by the FDA in 2023 under the trade name Exxua for major depressive disorder. The compound is structurally and mechanistically similar to buspirone: 5-HT1A affinity approximately 19 nM with intrinsic activity approximately 60 percent; minimal D2 affinity; active metabolite 1-PP. Distinct from buspirone in development trajectory (positioned for depression rather than anxiety) and in being formulated as extended-release for once-daily dosing. The approved indication is MDD; the principal selling point versus SSRIs is absence of sexual dysfunction (a major SSRI tolerability complaint). Plasma half-life is 18 hours (ER formulation); metabolism is via CYP3A4. Used as a reference 5-HT1A partial agonist with depression-focused clinical development.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.